You have read all your free articles, to continue reading subscribe to read the rest of this content.
The Gothenburg based company has announced that an article has been published in Neurology, from the American Academy of Neurology, describing data from the company’s IPO-001 pharmacokinetic cross-over study. In a pharmacokinetic cross-over study comprising 18 evaluable subjects with advanced PAlready a subscriber Login You have read all your free…
Pila Pharma has announced that the preclinical toxicological three-month studies of the active substance XEN-D0501 has begun. Pila Pharma is, as previously announced, preparing a clinical phase 2b study of the drug candidate XEN-D0501 for type 2 diabetes. Previously, XEN-D0501 has been evaluated Already a subscriber Login You have read…
Medivir announces the completion of the phase II clinical study of the topical, skin-directed histone deacetylase (HDAC) inhibitor, remetinostat, in patients with early stage CTCL. The trial included 60 patients with the mycosis fungoides (MF) variant of CTCL, who were randomized to receive eitheAlready a subscriber Login You have read…
Lytix Biopharma has announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for LTX-315, an oncolytic molecule in development for various solid tumors. “This is a significant milestone for Lytix Biopharma, as it clears aAlready a subscriber Login You have read…
